Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tagrisso Plus Chemo Now Allowed to Treat EGFR Lung Cancer: AstraZeneca
June 26, 2024
- JCR, Takeda End Global Collab for Hunter Syndrome Therapy
June 26, 2024
- Rexulti’s PTSD Filing Clinches FDA Acceptance for Review: Otsuka/Lundbeck
June 26, 2024
- Santen CEO Snares 191 Million Yen in Annual Pay, Workforce Down by 131
June 26, 2024
- Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
- Recordati Japan Names Shoji Kuroyama as New President
June 25, 2024
- Takeda Scores EU Approval for Colorectal Cancer Med Fruzaqla
June 25, 2024
- BMS Gears Up for Return to Neuroscience with KarXT, Explores Path toward Japan Rollout Too
June 25, 2024
- Shionogi Workforce Down 341 after Voluntary Buyout Program
June 24, 2024
- Axcelead’s Next CEO Eyes Sales of 120 Billion Yen, Ramp-Up in Mega Pharma Orders
June 21, 2024
- IBL Pairs Up with South Korea’s SML for SFTS Therapy Development
June 21, 2024
- SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
- Astellas CEO’s Pay Tops 400 Million Yen in FY2023: Securities Report
June 21, 2024
- Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
- Tsumura Looks to Plant “Guidepost” for Development of Botanical Drugs in US
June 20, 2024
- Healios, Astellas Team Up for RPE Cell Production Method
June 20, 2024
- Zeria Doles Out Acofide Rights to Agastra in Europe, North America
June 20, 2024
- Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
- J-TEC Files JACC for Label Expansion into Knee Osteoarthritis
June 19, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…